• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Judge mulls FDA control over compounded drugs

September 1, 2006
Jennifer Fiala

Midland, Texas - The Food and Drug Administration's (FDA) regulatory authority over compounded veterinary medicines hinges on a ruling by a judge who's already hinted at limiting the agency's control in the human sector.

MIDLAND, TEXAS — The Food and Drug Administration's (FDA) regulatory authority over compounded veterinary medicines hinges on a ruling by a judge who's already hinted at limiting the agency's control in the human sector.

The Food and Drug Administration's (FDA) regulatory authority over compounded veterinary medicines hinges on a ruling by a judge who's already hinted at limiting the agency's control in the human sector.

U.S. District Court Judge Robert Junell's written decision regarding compounded animal drugs was expected soon after he noted from the bench in May that such drugs for human use are not subject to FDA approval. Compounds fail to qualify as new, unapproved drugs in human medicine, but more study was needed for the case's animal drug element, he contended. In July, Junell invited another round of briefing on the animal drug issue before handing down a final verdict, not released by presstime.

Advertisement

The lawsuit, filed by 10 pharmacists, contests FDA's position that it has carte blanche under the Food Drug and Cosmetic Act to enter and inspect compound pharmacies, which are regulated by state pharmacy boards. It also challenges FDA's requirements that compound pharmacies sign the agency's Compliance Policy Guide before participating in trade shows, court documents show.

While conflict between FDA and compounders has ensued for years, the debate came to a head in 2004, when the agency issued letters to state pharmacy boards that all compounding from bulk substances was subject to regulatory authority and inspection. While the struggle has since fizzled, FDA maintains that compounded drugs create new medicines to be policed for safety and efficacy. For now, FDA employs what it calls enforcement discretion to determine when to act against a compounding pharmacy and when to look the other way.

"Clearly, FDA reads the law much differently than compounding does," says L.D. King, executive director of the International Academy of Compounding Pharmacists. "According to FDA, every compounded medication is an unapproved drug, therefore, it is illegal."

FDA officials refused to comment on the ongoing case but noted a willingness to appeal any unfavorable decision. Dr. Kent McClure, general counsel for the Animal Health Institute, represents pharmaceutical manufacturers and comes out on the side of FDA. So far, the judge has only "shared some thoughts," he says.

"There's nothing to appeal until there's a written order signed by the judge," McClure says. "He's reserving the question of animal drugs and voices some apprehension. It's anybody's guess when the written order will come out. That's where the real meat of this is going to come."

Related Content:

Regulatory
What you need to know about GFI #256 and the changing landscape of compounding medicine
What you need to know about GFI #256 and the changing landscape of compounding medicine
3 common misconceptions in controlled substance regulations
3 common misconceptions in controlled substance regulations
FDA hosts virtual listening session on regulation of animal food
FDA hosts virtual listening session on regulation of animal food

Advertisement

Latest News

What's new with the "Dentistry Lane" across the veterinary profession?

Meet the BlackDVM Network

Study finds certain canine breeds should be screened for cancer at young ages

AVMA releases 2 videos informing pet parents on pet dental care

View More Latest News
Advertisement